Carol Greve-Philips is a senior business development executive with wide experience across different types of transactions, therapeutic modalities, corporate organizations and geographies. She has planned and executed licenses with academic institutions and private companies, developed partnerships and collaborations, and engaged in as both a buyer and a seller.
As a senior executive in Corporate Development at Genzyme she was responsible for the business development activities of the flagship Rare Disease business, licensing new products for the portfolio of the business. She later joined Spark Therapeutics during its first three years as Head of Corporate Development and Strategy, completing transactions with Pfizer, Genable LLC, the University of Massachusetts Medical School, and Oklahoma Medical Research Foundation among others. Consulting to both Quad Technologies and Abfero Pharmaceuticals Carol was the business development architect behind the sale of both companies to BioTechne and Pharmacosmos, respectively. With more than 40 years across the biotech and pharmaceutical industries Carol is an experienced problem solver who enables agreement between motivated partners.
